A Randomized, Double-Blind, Placebo-Controlled Study of Diazoxide Choline Controlled-Release Tablet (DCCR) in Patients With Prader-Willi Syndrome

Trial Profile

A Randomized, Double-Blind, Placebo-Controlled Study of Diazoxide Choline Controlled-Release Tablet (DCCR) in Patients With Prader-Willi Syndrome

Not yet recruiting
Phase of Trial: Phase III

Latest Information Update: 28 Feb 2018

At a glance

  • Drugs Diazoxide (Primary)
  • Indications Prader-Willi syndrome
  • Focus Registrational; Therapeutic Use
  • Sponsors Soleno Therapeutics
  • Most Recent Events

    • 20 Feb 2018 According to a Soleno Therapeutics media release, the study design has been disscused in the End-of-Phase 2 Meeting with the US Food and Drug Administration (FDA).
    • 19 Feb 2018 Status changed from planning to not yet recruiting.
    • 22 Nov 2017 According to a Soleno Therapeutics media release, the company is advancing the DCCR phase III clinical program in Prader-Willi syndrome in early 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top